A Phase IB, Study to Investigate the Effect of Ketoconazole, a CYP3A4 Inhibitor, on Oral LBH589 and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced Solid Tumors.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Levels of LBH589 in the blood on days 1, 5, 8, 9 and 10 of first cycle
United States: Food and Drug Administration
|Nevada Cancer Institute||Las Vegas, Nevada 89135|